Plaque Psoriasis - Columbus OH

Summary:

Click image to enlarge

To evaluate the efficacy of TAK-279 30 mg orally administered once daily (QD) for 16 weeks, compared to placebo, in subjects with moderate-to-severe plaque psoriasis.
 

1. Aged 18 years or older
2. Has a diagnosis of chronic plaque psoriasis for ≥6 months prior to the screening visit
3. Has plaque psoriasis covering ≥10% of his or her total BSA at screening
4. May not have a history of cancer or lymphoproliferative disease within 5 years, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma
5. May not have a history of clinically significant drug or alcohol abuse within 12 months

Qualified Participants May Receive:

• Medical Care at no cost
• Up to $2, 175.00 for time and travel